{"id":1408,"date":"2009-04-20T16:52:37","date_gmt":"2009-04-20T15:52:37","guid":{"rendered":"http:\/\/localhost.localdomain\/wpmu\/htb\/?p=1408"},"modified":"2013-08-16T14:31:18","modified_gmt":"2013-08-16T14:31:18","slug":"nevirapine-fluconazole-and-tb-treatment","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/1408","title":{"rendered":"Nevirapine: fluconazole and TB treatment"},"content":{"rendered":"<p><strong>hiv-druginteractions.org<\/strong><\/p>\n<p><strong>Pharmacokinetics of nevirapine (200 mg twice daily) and fluconazole ( 200 mg three times weekly) were determined in 27 HIV+ patients and compared to data from 22 HIV+ subjects receiving nevirapine (200 mg twice daily) and placebo.<\/strong> [1]<\/p>\n<p>Fluconazole increased nevirapine AUC by 33 % (from 34297 ng.h\/ml to 45685 ng.h\/ml); increases were also observed in median Cmax (5028 vs 6354 ng\/ml) and Cmin (3709 vs 5116 ng\/ml). Despite the increase in nevirapine exposure, there was no evidence of increased hepatotoxicity.<\/p>\n<p>Nevirapine trough concentrations were determined in 20 Ugandan children (age 1.2-11.3 years), seven of whom were receiving concomitant anti-TB therapy which included rifampicin. [2]<\/p>\n<p>Median concentrations in the non-rifampicin group were 4204 ng\/ml (range 834 to 15976 ng\/ml). Concentrations in the rifampicin group were lower (2920 ng\/ml, range 1668 to 9978 ng\/ml), with 57% of the children in this group having subtherapeutic concentrations.<\/p>\n<p>References:<\/p>\n<ol>\n<li>Wakeham K, et al. Coadministration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. 16th CROI, Montreal, 2009. Abstract 703. Abstract 700. <a href=\"http:\/\/www.retroconference.org\/2009\/Abstracts\/34543.htm\"><br \/>\nhttp:\/\/www.retroconference.org\/2009\/Abstracts\/34543.htm<\/a><\/li>\n<li>Barlow-Mosha L, et al. Nevirapine concentrations in HIV-infected Ugandan children on adult fixed-dose combination tablet ART, with and without rifampicin-based treatment for active M. tuberculosis infection. 16th CROI, Montreal, 2009. Abstract 909. <a href=\"http:\/\/www.retroconference.org\/2009\/Abstracts\/35604.htm\"><br \/>\nhttp:\/\/www.retroconference.org\/2009\/Abstracts\/35604.htm<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>hiv-druginteractions.org Pharmacokinetics of nevirapine (200 mg twice daily) and fluconazole ( 200 mg three times weekly) were determined in 27 HIV+ patients and compared to data from 22 HIV+ subjects receiving nevirapine (200 mg twice daily) and placebo. [1] Fluconazole &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,37],"tags":[63],"class_list":["post-1408","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-tb-coinfection","tag-croi-2009"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/1408","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=1408"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/1408\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=1408"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=1408"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=1408"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}